echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Biopharma's selective RET inhibitor approved for clinical use

    China Biopharma's selective RET inhibitor approved for clinical use

    • Last Update: 2022-04-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On March 29, Sino Biopharmaceutical announced that the Group's self-developed Class 1 anti-tumor innovative drug "FHND5071" was approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of advanced solid tumors


    FHND5071 was developed by the research team of the group using computer-aided drug design and traditional drug design methods, and through the structure-activity analysis of medicinal chemistry, structure optimization, and in vitro and in vivo biological activity and pharmacokinetic (DMPK) screening.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.